Skip to content

NIV-Training in Hypercapnic COPD Patients

The Effects of Non-invasive Ventilation During Cycle Exercise Within a 3-week Pulmonary Rehabilitation Program in COPD Patients With Chronic Hypercapnic Respiratory Failure - a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03803358
Enrollment
30
Registered
2019-01-14
Start date
2019-01-07
Completion date
2021-07-27
Last updated
2021-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

CHRF, NIV, exercise training

Brief summary

The aim of the study is to investigate the additional effects of the use of NIV during exercise within a 3-week PR program on exercise capacity in COPD patients with chronic hypercapnic respiratory failure.

Detailed description

Scientific Background/ Rationale: Quality of life and exercise tolerance are commonly reduced in people with chronic obstructive pulmonary disease (COPD), especially in people with chronic hypercapnic respiratory failure (CHRF). Endurance exercise training as part of a pulmonary rehabilitation (PR) programme is an important treatment for people with COPD and has been shown to improve quality of life, exercise tolerance and physical activity. However, individuals with CHRF may have difficulties performing endurance exercise at an adequate training intensity to achieve the desired physiological changes. Non-invasive ventilation (NIV) is a method of providing breathing support using a ventilator and is usually delivered via a full face mask. A recent study showed that during a single exercise session in people with CHRF, NIV dramatically improves exercise tolerance and reduces breathlessness. Consequently, NIV used over a complete exercise training program may allow people with COPD and CHRF to exercise at a higher intensity to achieve greater improvement in exercise tolerance, quality of life and physical activity. So far this has only been tested in a small number of studies with small numbers of participants, and none with CHRF. It is currently not known from literature whether the demonstrated benefits of NIV during exercise training are clinically worthwhile or cost-effective. Aims The aim of the study is to investigate the additional effects of the use of NIV during exercise within a 3-week PR program on exercise capacity in COPD patients with chronic hypercapnic respiratory failure. Hypothesis It is assumed that a 3-week exercise training program with additional NIV, using titrated pressures, reduces the work of breathing. With this, it is theorized, COPD patients with CHRF are able to train for a longer duration and/ or with higher training intensities over the course of the training program and may achieve better PR outcomes. Primary Hypothesis: H.0: COPD-Patients with CHRF have the same increase in exercise capacity (endurance cycle time) when training with additional NIV as without NIV, during a 3-week PR program. H.1: COPD-Patients with CHRF have a superior increase in exercise capacity (endurance cycle time) when training with additional NIV as without NIV, during a 3-week PR program. Main Objective To determine if NIV during exercise is a useful tool for increasing exercise tolerance in hypercapnic patients, exercise tolerance (cycle endurance time) will be measured without NIV at PR admission/ discharge Materials and Method A total of 26 COPD patient (age: 40-80 years) in GOLD Stages IV diagnosed with CHRF, already treated with nocturnal NIV and referred for a comprehensive PR program will be recruited and randomized into two groups: 1) exercise with NIV during exercise (nocturnal NIV will continue) and 2) control group - exercise without NIV during exercise (nocturnal NIV will continue). Initially, patients will perform a maximum cardiopulmonary test to determine the Peak Work Rate (WRpeak). On a separate day, patients will perform a cycle endurance test (CET) at 75%WRpeak without NIV using oxygen as prescribed, if needed. TcPCO2, heart rate and SpO2 via SenTec will be measured continuously during CET. In addition to the continuously recorded data, dyspnoea/ respiratory effort/ leg-fatigue (10-point Borg scale), capillary blood gases and the arterial blood pressure will be taken at the beginning/ end/ recovery/ isotime of the CET.

Interventions

OTHERexercise training with non-invasive ventilation

In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.

OTHERstandard exercise training without NIV

In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.

Sponsors

Löwenstein Medical GmbH & Co. KG
CollaboratorUNKNOWN
Bad Reichenhaller Forschungsanstalt
CollaboratorUNKNOWN
Schön Klinik Berchtesgadener Land
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

A total of 26 COPD patients in GOLD Stages IV diagnosed with CHRF, already treated with nocturnal NIV and referred for a comprehensive PR program will be recruited and randomized into two groups: 1) exercise with NIV during exercise (nocturnal NIV will continue) and 2) control group - exercise without NIV during exercise (nocturnal NIV will continue).

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of very severe COPD Gold Stage IV * Age: 40-80 years * PaCO2 \>50mmHg (at rest, during sleep or exercise) * Implemented nocturnal non-invasive ventilation therapy

Exclusion criteria

* Concomitant cardiovascular, orthopaedic or neurological conditions that are likely to be the primary impairment to exercise performance * Other significant pulmonary disease which could affect exercise or NIV (e.g. asthma) * BMI \> 35 kg/m2 * Inability to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Exercise toleranceDay 1 and Day 21Change in cycle endurance time without NIV within PR

Secondary

MeasureTime frameDescription
Oxygen saturationDay 1 and Day 21Change in Oxygen Saturation during CET, recorded via SenTec (Switzerland, Therwill)
Heart rateDay 1 and Day 21Change in Heart Rate during CET, recorded via SenTec (Switzerland, Therwill)
Partial pressure of carbon dioxideDay 1 and Day 21Change in partial pressure of carbon dioxide pre/ post CET, recovery, isotime, recorded via capillary taken blood gases
Partial pressure of oxygenDay 1 and Day 21Change in partial pressure of oxygen pre/ post CET, recovery, isotime, recorded via capillary taken blood gases
Arterial blood pressureDay 1 and Day 21Change in arterial blood pressure pre/ post CET, recovery, isotime
Patients perception - DyspnoeDay 1 and Day 21Change in perceived dyspnoea /respiratory effort pre/ post CET, recovery, isotime recorded via Borg Scale
Partial pressure of transcutaneous carbon dioxideDay 1 and Day 21Change in partial pressure of carbon dioxide levels during CET, recorded via SenTec (Switzerland, Therwill)
Patients Quality of life - Chronic Respiratory QuestionnaireDay 1 and Day 21Change in Chronic Respiratory Questionnaire
Patients Quality of life - Severe Respiratory Insufficiency QuestionnaireDay 1 and Day 21Change in Severe Respiratory Insufficiency Questionnaire
Anxiety and DepressionDay 1 and Day 21Change in Hospital Anxiety and Depression Scale
Maximal voluntary muscle contractionDay 1 and Day 21Change in muscle contraction force (m. rectus femoris) recorded via MicroFet
Patients perception to physical Training with additional NIVDay 1 and Day 21Patients in the Intervention Group will be interviewed how they perceived the Treatment, via a questionnaire with open- and closed ended questions
Patients perception - leg fatigueDay 1 and Day 21Change in perceived leg fatigue pre/ post CET, recovery, isotime recorded via Borg Scale

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026